Select Medical Technology and Devices Portfolio
Fidelity Select Portfolios · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
Select Medical Technology and Devices Portfolio is an actively managed U.S. equity fund. 13% of FSMEX’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 92% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2026 Q2
Medical Technology and Devices Portfolio seeks capital appreciation.
The fund invests at least 80% of assets in common stocks of companies principally engaged in medical device and equipment manufacturing, drug discovery services, or health care information technology, using fundamental analysis of financial condition and industry position. The fund may invest in both domestic and foreign issuers. Because the fund's classification of companies as principally engaged in these activities relies on asset, income, sales, or profit metrics or third-party industry classifications, the fund's holdings may diverge from what different analysts would consider the core medical technology sector.
| Share class | Expense ratio |
|---|---|
| FSMEX | 0.62% |
Portfolio turnover 54.00% · as of 2026 Q2
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.52% |
| Cash & short-term | 3.37% |
| Bonds | 0.04% |
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 91.5% |
| Cash | 3.3% |
| Other | 2.7% |
| International | 2.5% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Portfolio growth profile
How much of the fund’s stock holdings are in fast-growing companies · as of 2026 Q2
Share of the fund’s equity (by value) in companies whose trailing five-year revenue — or net-income — growth ranks in the top 25% of U.S. public companies. Foreign and newly-listed holdings are excluded, so the figure covers only part of the book. From SEC filings — not investment advice. How we measure this.
Latest quarter
What changed since the fund's previous filing
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
May 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
Debt profile
What this fund holds — value-weighted across its bond and securitized long positions · as of 2026-05-31
Share of the fund's debt by how its coupon behaves — the fact that decides whether a rate move reaches this portfolio at all.
| Fixed rate | 100.0% |
Share of the fund's debt value in each maturity band, shortest first.
| <1y | 100.0% |
Based on what filers reported; a filer that never reported a flag also reads as none.
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| DHR | DANAHER CORPDHR | 15.09% | $182.67 | $449.37M | 2.5M |
| TMO | THERMO FISHER SCIENTIFIC INCTMO | 14.06% | $492.51 | $418.63M | 850.0K |
| ISRG | INTUITIVE SURGICAL INCISRG | 7.45% | $424.64 | $221.87M | 522.5K |
| BSX | BOSTON SCIENTIFIC CORPBSX | 5.11% | $48.31 | $152.18M | 3.1M |
| EW | EDWARDS LIFESCIENCES CORPEW | 4.21% | $86.47 | $125.38M | 1.4M |
| SYK | STRYKER CORPSYK | 4.18% | $305.09 | $124.48M | 408.0K |
| ABT | ABBOTT LABORATORIESABT | 3.85% | $85.60 | $114.70M | 1.3M |
| WAT | WATERS CORPWAT | 3.27% | $383.57 | $97.43M | 254.0K |
| A | AGILENT TECHNOLOGIES INCA | 3.21% | $135.53 | $95.70M | 706.1K |
| WST | WEST PHARMACEUTICAL SVCS INCWST | 3.09% | $322.81 | $92.00M | 285.0K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-05-31 — not a live quote, and not what the fund paid.
Top 10 positions are 63.54% of net assets, top 25 90.24%, across 53 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free